8/18/2015 | PP | Rigel Pharmaceuticals arranges $30 million at-the-market sale of stock
|
5/25/2011 | PP | Rigel Pharmaceuticals to price a public offering of its common shares
|
12/14/2010 | CVHYPF | Rigel files $125 million shelf covering stock, preferreds and debt
|
11/7/2006 | BT | Rigel reports net loss of $11.4 million for third quarter
|
10/19/2006 | BT | Rigel to begin clinical trials of new JAK3 inhibitor compound in 2007
|
9/26/2006 | BT | JMP reiterates Rigel at market perform
|
9/19/2006 | BT | Rigel gets $3 million milestone as Serono starts R763 trial
|
9/14/2006 | BT | Rigel begins phase 2 clinical trial of R788 for rheumatoid arthritis
|
8/2/2006 | BT | Rigel Pharmaceuticals has net loss for the second-quarter of $2.3 million
|
7/19/2006 | BT | Rigel's Janus Kinase 3 inhibitors show benefit in organ transplant model
|
6/13/2006 | BT | Rigel gets $1 million milestone payment from Merck
|
5/17/2006 | BT | Rigel gets $5 million from Pfizer for R343 asthma development
|
5/2/2006 | BT | Rigel reports net loss shrinks to $8.5 million for first quarter
|
1/30/2006 | BT | Rigel receives milestone payment from Merck for ligase research
|
1/26/2006 | BT | Rigel earns $5 million milestone from Serono for oral anticancer drug R763
|
12/20/2005 | BT | Rigel begins phase 1 trial of R788 rheumatoid arthritis compound, files application for R763
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/16/2005 | BT | Rigel reiterated by JMP at market perform
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
12/7/2005 | BT | Rigel's R406/788 shows promise for treating blood disorders, study finds
|
12/2/2005 | BT | White Mountain cuts Rigel to hold
|
12/1/2005 | BT | Rigel's R112 fails to improve allergic rhinitis in phase 2 trial
|
12/1/2005 | BT | JMP downgrades Rigel to market perform
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/28/2005 | BT | Rigel study shows potential for UHRF1 as cancer target
|
11/14/2005 | BT | Rigel study shows R406 blocks activation of cells that promote swelling, inflammation of rheumatoid arthritis
|
11/10/2005 | BTCV | Rigel files $200 million shelf
|
10/25/2005 | BT | JMP reiterates Rigel's market outperform rating
|
10/25/2005 | BT | Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
|
8/4/2005 | BT | Rigel reiterated by JMP at market outperform
|
7/21/2005 | BT | Rigel greenshoe fully exercised in closing of $81.9 million stock offering
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/15/2005 | BT | New Issue: Rigel upsized $75.7 million secondary stock sale prices at $20.75 versus $21.56 close
|
7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
7/11/2005 | BT | Market Commentary: Accentia runs into resistance; Canadian biotechs tap PIPEs; eyes on Genentech; Mylan up
|
7/11/2005 | BT | Rigel to sell 3 million shares
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|